The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL353335     8-chloro-2-phenyl-4- azabicyclo[5.4.0]undec...

Synonyms: SureCN398776, Skf-81297, CCG-205236, SKF-81,297, Lopac0_001162, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of SKF 81297


Psychiatry related information on SKF 81297

  • In general, SKF-81297 produced a biphasic effect on motor activity (locomotor and rearing activity), which consisted of an initial short inhibition followed by a long-lasting stimulation [5].
  • However, while SKF-81297 dose-dependently increased response latency, SCH-23390 did not [6].
  • The D1 agonists SKF 38393 and SKF 81297 (3.0 mg/kg, i.p.) significantly reduced the latency period to find a hidden platform in the Morris Water Maze, reflecting improved cognitive functions, while the D1 antagonist SCH 23390 (0.05 mg/kg, i.p.) had no overall significant effect [7].
  • In this study, the behavioural response to dopamine D1-like receptor agonists (SKF 38393, SKF 81297 and SKF 77434) and D2-like receptor agonists (quinpirole and RU 24213), administered alone and in combination to rats treated repeatedly with electroconvulsive shock (five ECS over 10 days) or sham, was tested [8].
  • On the other hand, apomorphine, the D2 agonist quinpirole, or combination of quinpirole and the D1 agonist SKF 81297 induced more stereotyped behavior such as biting or head movements in D2L-/- mice (which express only D2S) than in wild type mice [9].

High impact information on SKF 81297

  • A D1 agonist, SKF 81297, inhibited (37.6 +/- 4.7%) NHE activity in brush border membranes of normotensive F2s (systolic blood pressure < 140 mm Hg, n = 7) but not in hypertensive F2s (n = 21) [10].
  • Whole-cell patch clamp recordings of acutely dissociated hippocampal pyramidal cells revealed that the D1 dopamine receptor agonist SKF 81297 reduces peak Na(+) current amplitude by 20.5%, as reported previously [11].
  • SKF 81297, a D1-like agonist, mimicked DA-induced effect on evoked IPSCs (IC50, 10.9 microM), whereas R(-)-TNPA or (-)-quinpirole, D2-like agonists (30 microM), had little or no effect on the amplitude of evoked IPSCs [12].
  • Contrary to this, chronic intermittent stimulation of the motor cortex down-regulated cocaine-induced gene expression in the striatum, but enhanced striatal gene expression induced by a full D1 receptor agonist (SKF 81297) and did not change the early-gene response elicited by a D2 receptor antagonist (haloperidol) [13].
  • D1-D2 receptor heterooligomers were internalized when the receptors were coactivated by dopamine or either receptor was singly activated by the D1-selective agonist (+/-)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297) or the D2-selective agonist quinpirole [14].

Chemical compound and disease context of SKF 81297


Biological context of SKF 81297

  • The D(1) receptor agonist SKF 81297 increased Ser845 phosphorylation in a concentration- dependent manner, with marked increases occurring within 5 min [17].
  • D1 agonists including SKF 81297, SKF 82958, and R(+)-6-Br-APB produced dose-dependent increases in the frequencies of stationary postures and head movements and had little or no effect on either huddling or scratching [18].
  • The D1 agonist (+/-)-6-chloro-7, 8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297) also produced increases in blood pressure and heart rate but was much less potent than either cocaine or SKF 82958 [19].
  • We investigated sex differences in the motor responses to the full and selective dopamine D1-like receptor agonist, (+/-)-6-chloro-7,8-dihydroxyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF-81297; 0.3, 3, and 10 mg/kg, s.c.), in non-habituated adult rats [20].

Anatomical context of SKF 81297

  • Surface GluR1 labeling on processes of medium spiny neurons and interneurons was increased by brief (5-15 min) incubation with a D1 agonist (1 microm SKF 81297) [21].
  • Here, we investigated the effects of a full and selective D1 receptor agonist, SKF-81297, on motor activity and expression of the plasticity-associated gene, c-fos, in the prefrontal cortex and striatum of juvenile and adolescent male rats [5].
  • Furthermore, the inhibitory effects on striatal nerve cell firing rate by the D1 receptor agonist SKF 81297 were not different in noninnervated or reinnervated areas of the striatum compared to the control side as seen from the dose-response curves [22].
  • Dihydrexidine, SKF 81297 and A-77636 were free of rate effects on midbrain dopamine neurons (up to 10.2 mg/kg) and also did not antagonize the inhibitory effects of quinpirole [23].
  • Microinfusion of the D2/3 dopamine receptor antagonist sulpiride ((S)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide) (1.0 mug) into the nucleus accumbens shell 10 minutes prior to SKF-81297 (1.0 mug) blocked the ability of this D1-like dopamine receptor agonist to reinstate cocaine seeking [24].

Associations of SKF 81297 with other chemical compounds


Gene context of SKF 81297

  • A maximally effective concentration of SpcAMPS (10 microm) occluded the effect of SKF 81297 (1 microm) on GluR1 externalization [30].
  • We show that, in striatal slices, the D2 receptor agonist, quinpirole, strongly inhibits the phosphorylation of DARPP-32 induced by either the D1 receptor agonist, SKF 81297, or the A2A receptor agonist, CGS 21680 [31].
  • The full D1 agonist SKF 81297, when administered systemically to control animals, stimulated a dose-dependent increase in locomotor activity [32].
  • RESULTS: Reversal of sensitization was produced by repeated administration of either a D1-class agonist (SKF 81297) or the combination of an NMDA receptor antagonist and a D2-class agonist [33].
  • When studied in combination with a range of cocaine doses, treatment with the agonists SKF 83959, SKF 77434, SKF 81297, and the antagonist SCH 39166 produced overall rightward and downward shifts in the dose-response function for cocaine self-administration [34].

Analytical, diagnostic and therapeutic context of SKF 81297

  • Most interestingly, while prefrontal cortical perfusion of SKF 81297 (100 and 250 microM) had no significant effect on ACh release in post-pubertal sham-operated animals, it significantly stimulated ACh release to approximately 250% baseline at both doses in post-pubertal NVH-lesioned animals [35].
  • Moreover, by western blot analysis using an antibody specific for the phosphorylated PKA site Ser845 of GluR1, we observed a marked increase in phosphorylated GluR1 following a 10-min exposure of striatal neurons to 1 microM SKF 81297 [36].
  • After 8-17 days' withdrawal, rats received an intra-mPFC microinjection of the full D1 agonist, SKF 81297: 0, 0.03, 0.1 or 0.3 microg/side followed by an i.p. saline or cocaine injection (15 mg/kg, i.p.). The target sites were either the dorsal or ventral mPFC [37].
  • Just prior to reinstatement by immobilization stress or a cocaine priming injection (5 mg/kg, i.p.), a microinjection of the D1-like receptor antagonist SCH 23390 (0.01, 0.1 or 1.0 microg/side), or the D1-like receptor agonist SKF 81297 (0.1, 0.3 or 1.0 microg/side) was given into the medial prefrontal cortex [38].
  • Here, we examined the effects of local application of a dopamine Type I (D(1)) receptor-specific agonist, SKF 81297, in the PFC on the chronic-stress-induced depressive state using a rotarod test [39].


  1. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity. Lublin, H., Gerlach, J., Peacock, L. Psychopharmacology (Berl.) (1993) [Pubmed]
  2. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. Goulet, M., Madras, B.K. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  3. The effects of dopamine D-1 and D-2 receptor agonists on body temperature in male mice. Sánchez, C. Eur. J. Pharmacol. (1989) [Pubmed]
  4. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia. Lublin, H. Clinical neuropharmacology. (1995) [Pubmed]
  5. Alteration of dopamine D1 receptor-mediated motor inhibition and stimulation during development in rats is associated with distinct patterns of c-fos mRNA expression in the frontal-striatal circuitry. Diaz Heijtz, R., Scott, L., Forssberg, H. Eur. J. Neurosci. (2004) [Pubmed]
  6. Blockade or stimulation of D1 dopamine receptors attenuates cue reinstatement of extinguished cocaine-seeking behavior in rats. Alleweireldt, A.T., Weber, S.M., Kirschner, K.F., Bullock, B.L., Neisewander, J.L. Psychopharmacology (Berl.) (2002) [Pubmed]
  7. Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats. Hersi, A.I., Rowe, W., Gaudreau, P., Quirion, R. Neuroscience (1995) [Pubmed]
  8. Evidence that the enhancement of dopamine function by repeated electroconvulsive shock requires concomitant activation of D1-like and D2-like dopamine receptors. Smith, S.E., Sharp, T. Psychopharmacology (Berl.) (1997) [Pubmed]
  9. Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor. Fetsko, L.A., Xu, R., Wang, Y. Brain Res. (2003) [Pubmed]
  10. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. Albrecht, F.E., Drago, J., Felder, R.A., Printz, M.P., Eisner, G.M., Robillard, J.E., Sibley, D.R., Westphal, H.J., Jose, P.A. J. Clin. Invest. (1996) [Pubmed]
  11. Dopamine modulation of neuronal Na+ channels requires binding of A kinase-anchoring protein 15and PKA by a modified leucine zipper motif. Few, W.P., Scheuer, T., Catterall, W.A. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  12. Modulation of inhibitory transmission by dopamine in rat basal forebrain nuclei: activation of presynaptic D1-like dopaminergic receptors. Momiyama, T., Sim, J.A. J. Neurosci. (1996) [Pubmed]
  13. Shifts in striatal responsivity evoked by chronic stimulation of dopamine and glutamate systems. Canales, J.J., Capper-Loup, C., Hu, D., Choe, E.S., Upadhyay, U., Graybiel, A.M. Brain (2002) [Pubmed]
  14. D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. So, C.H., Varghese, G., Curley, K.J., Kong, M.M., Alijaniaram, M., Ji, X., Nguyen, T., O'dowd, B.F., George, S.R. Mol. Pharmacol. (2005) [Pubmed]
  15. SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Cools, A.R., Lubbers, L., van Oosten, R.V., Andringa, G. Neuropharmacology (2002) [Pubmed]
  16. A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Baldo, B.A., Jain, K., Veraldi, L., Koob, G.F., Markou, A. Pharmacol. Biochem. Behav. (1999) [Pubmed]
  17. D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures. Chao, S.Z., Lu, W., Lee, H.K., Huganir, R.L., Wolf, M.E. J. Neurochem. (2002) [Pubmed]
  18. Observational studies of dopamine D1 and D2 agonists in squirrel monkeys. Rosenzweig-Lipson, S., Hesterberg, P., Bergman, J. Psychopharmacology (Berl.) (1994) [Pubmed]
  19. Interactions between cocaine and dopamine agonists on cardiovascular function in squirrel monkeys. Schindler, C.W., Gilman, J.P., Bergman, J., Mello, N.K., Woosley, R.L., Goldberg, S.R. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  20. Sex differences in the motor inhibitory and stimulatory role of dopamine D1 receptors in rats. Heijtz, R.D., Beraki, S., Scott, L., Aperia, A., Forssberg, H. Eur. J. Pharmacol. (2002) [Pubmed]
  21. D1 dopamine receptor stimulation increases GluR1 surface expression in nucleus accumbens neurons. Chao, S.Z., Ariano, M.A., Peterson, D.A., Wolf, M.E. J. Neurochem. (2002) [Pubmed]
  22. Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum. Strömberg, I., Kehr, J., Andbjer, B., Fuxe, K. Exp. Neurol. (2000) [Pubmed]
  23. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393. Ruskin, D.N., Rawji, S.S., Walters, J.R. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  24. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat. Schmidt, H.D., Pierce, R.C. Neuroscience (2006) [Pubmed]
  25. Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. Edwards, S., Whisler, K.N., Fuller, D.C., Orsulak, P.J., Self, D.W. Neuropsychopharmacology (2007) [Pubmed]
  26. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Unger, E.L., Eve, D.J., Perez, X.A., Reichenbach, D.K., Xu, Y., Lee, M.K., Andrews, A.M. Neurobiol. Dis. (2006) [Pubmed]
  27. Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice. Cohen, C., Perrault, G., Sanger, D.J. Neuropharmacology (1997) [Pubmed]
  28. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Svenningsson, P., Lindskog, M., Rognoni, F., Fredholm, B.B., Greengard, P., Fisone, G. Neuroscience (1998) [Pubmed]
  29. Effects of AMPA and D1 receptor activation on striatal and nigral GABA efflux. Byrnes, E.M., Reilly, A., Bruno, J.P. Synapse (1997) [Pubmed]
  30. D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A. Mangiavacchi, S., Wolf, M.E. J. Neurochem. (2004) [Pubmed]
  31. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Lindskog, M., Svenningsson, P., Fredholm, B.B., Greengard, P., Fisone, G. Neuroscience (1999) [Pubmed]
  32. Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice. Dracheva, S., Xu, M., Kelley, K.A., Haroutunian, V., Holstein, G.R., Haun, S., Silverstein, J.H., Sealfon, S.C. Exp. Neurol. (1999) [Pubmed]
  33. Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Li, Y., White, F.J., Wolf, M.E. Psychopharmacology (Berl.) (2000) [Pubmed]
  34. Modulation of cocaine and food self-administration by low- and high-efficacy D1 agonists in squirrel monkeys. Platt, D.M., Rowlett, J.K., Spealman, R.D. Psychopharmacology (Berl.) (2001) [Pubmed]
  35. Alterations in dopaminergic modulation of prefrontal cortical acetylcholine release in post-pubertal rats with neonatal ventral hippocampal lesions. Laplante, F., Srivastava, L.K., Quirion, R. J. Neurochem. (2004) [Pubmed]
  36. D1 dopamine receptor-induced cyclic AMP-dependent protein kinase phosphorylation and potentiation of striatal glutamate receptors. Price, C.J., Kim, P., Raymond, L.A. J. Neurochem. (1999) [Pubmed]
  37. Activation of dopamine D1 receptors in the medial prefrontal cortex produces bidirectional effects on cocaine-induced locomotor activity in rats: effects of repeated stress. Sorg, B.A., Li, N., Wu, W., Bailie, T.M. Neuroscience (2004) [Pubmed]
  38. Manipulation of dopamine d1-like receptor activation in the rat medial prefrontal cortex alters stress- and cocaine-induced reinstatement of conditioned place preference behavior. Sanchez, C.J., Bailie, T.M., Wu, W.R., Li, N., Sorg, B.A. Neuroscience (2003) [Pubmed]
  39. Dopamine-receptor stimulation in the prefrontal cortex ameliorates stress-induced rotarod impairment. Mizoguchi, K., Yuzurihara, M., Nagata, M., Ishige, A., Sasaki, H., Tabira, T. Pharmacol. Biochem. Behav. (2002) [Pubmed]
WikiGenes - Universities